Stockwatch: Sanofi's insulin war
This article was originally published in Scrip
Despite missing analyst consensus estimates of its quarterly sales, Merck & Co's earnings beat estimates by 2% thanks to lower R&D spending and were described as "solid", "robust" and "fairly in-line" by Jefferies, Citigroup and JP Morgan, respectively (scripintelligence.com, 28 October 2014). In truth, Merck and Bristol- Myers Squibb (BMS) (both of which we own) are likely to be given free passes on whatever their results will be, at least for the next couple of quarters, as no one wants to get in the way of the recent and imminent US approval and launch of their new products for the immunotherapy of cancer, Keytruda (pembrolizumab) and Opdivo (nivolumab), respectively. Indeed BMS' financial results from the previous week were almost a side-show to the hotly anticipated results of the CheckMate-063 clinical trial of Opdivo in lung cancer. These results were duly delivered last week showing an impressive one year survival rate of 41% in this difficult-to-treat population (scripintelligence.com, 31 October 2014).
You may also be interested in...
Biogen’s poor third-quarter results cannot be blamed solely on the pandemic. Pipeline attrition and underperformance in most franchises pushes all the risk onto a dubious throw of the regulatory dice.
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.